Physician profile
James P Leu
NPI 1841453677
$1,079.70
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $764 · 2020: $315.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $346.17 | 2019-2020 | |
| Lilly USA, LLC | $192.72 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $172.70 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.26 | 2019-2020 | |
| Molnlycke Health Care US, LLC | $77.97 | 2019 | |
| Sanofi-Aventis U.S. LLC | $58.33 | 2019-2020 | |
| Insulet Corporation | $56.31 | 2019 | |
| Shire North American Group INC | $29.36 | 2019 | |
| Cardiovascular Systems INC. | $23.84 | 2019 | |
| Abbott Laboratories | $17.71 | 2019 | |
| Radius Health, INC. | $14.79 | 2019 | |
| Medtronic Minimed, INC. | $11.54 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Leu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.